News and Trends 15 May 2018 An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […] May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 11 May 2018 This Oxford Biotech is Using DNA to Find New Peptide Drugs Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using DNA to tag potential therapeutic proteins. Mission: Orbit Discovery develops peptide drugs for a range of conditions including metabolic, autoimmune and cardiovascular diseases using beads to connect peptides to the DNA that encodes them and see how well the peptides […] May 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2018 FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […] May 3, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 12 Apr 2018 Graphene Skin Patch Measures Blood Sugar Without a Needle Researchers in the UK have developed a skin patch that measures blood sugar levels without the prick of a needle by pulling fluid out from between hair follicles. The technology could be used for both type 1 and type 2 diabetes patients. Diabetes is a major global health problem, with the World Health Organization stating 422 […] April 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to […] March 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 Oxford Firm Develops Better Test for ALS Diagnosis Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […] March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 New Antibiotic for MRSA Infections is Ready for US Clinical Trials Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […] March 15, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 This Oxford Spin-out Could be Printing New Body Parts The Oxford spin-out OxSyBio has secured £10M (€11,26M) to develop a 3D tissue printer that uses liquid droplets to design and regenerate tissues. Founded in 2014, OxSyBio is developing a technology to 3D print living tissues in order to replace body parts that are damaged by disease or injury. The substantial Series A funding was provided by Woodford Investment […] March 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2018 A Flick of a Switch Can Cause Age-Related Brain Deterioration Switching certain genes on or off causes the premature aging of stem cells that repair the brain. Identifying them could provide a target for new therapeutic approaches against neurodegenerative diseases. Scientists at the Babraham Insitute in Cambridge and the University of Sapienza in Rome have identified a number of genes involved in the aging of […] March 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2018 Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […] March 6, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […] February 28, 2018 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […] February 27, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email